Decreased Expression of Prox1 Is Associated With Postoperative Recurrence in Crohn's Disease.
Decreased Expression of Prox1 Is Associated With Postoperative Recurrence in Crohn's Disease.
复制标题
Prox1 表达降低与克罗恩病术后复发相关。
DOI：
10.1093/ecco-jcc/jjy091
复制
发表时间：
2018
影响因子：
8
通讯作者：
Zhu Weiming
中科院分区：
文献类型：
--
作者：
Shen Weisong;Li Yi;Cao Lei;Cai Xingchen;Ge Yuanyuan;Zhu Weiming
BackgroundProx1 是淋巴管生成和淋巴功能必需的转录因子。本研究的目的是评估Prox1的表达与克罗恩病[CD]术后复发的相关性。方法纳入40例接受回结肠切除术的CD患者。使用免疫组织化学检测 Prox1 和 D2-40 的表达水平。使用蛋白质印迹和定量聚合酶链反应 [Q-PCR] 检测新鲜 CD 标本中 Prox1、VEGFR3 和 VEGFC 蛋白的表达水平。内镜下复发被用作终点。患者分为两组：内镜下复发[R+组]和无内镜下复发[R-组]。结果通过免疫组织化学和蛋白质印迹检测，CD中Prox1蛋白表达显着高于正常组织[p<0.05]。相互关系分析显示 Prox1 表达与淋巴管密度之间存在显着相关性 [p<0.001，r = 0.823]。 Prox1 表达与内脏脂肪面积 [VFA] 之间也存在显着相关性 [p= 0.002，r = -0.469]。 R- 组患者的 Prox1 表达显着高于 R+ 组患者 [21.08 ± 1.61 vs 15.64 ± 1.17，p= 0.011]。此外，R+ 组患者的淋巴管密度值低于 R- 组患者 [6.02 ± 0.39 vs 8.13 ± 0.59，p= 0.004]。此外，R- 组和 R+ 组患者之间的 VFA 存在显着差异 [64.43 ± 7.76 与 90.44 ± 6.11，p= 0.016]。除了Prox1之外，还发现VEGFC/VEGFR3增加，这通过Q-PCR进一步证实。结论Prox1表达可以作为CD患者预防复发的保护因素。 Prox1 的治疗作用可能会导致治疗方法的改进。
BackgroundProx1 is a transcription factor necessary for lymphangiogenesis and lymphatic function. The aim of the study was to assess the correlation between the expression of Prox1 and postoperative recurrence in Crohn’s disease [CD].MethodsForty CD patients who underwent ileo-colonic resection were included. Expression levels of Prox1 and D2-40 were detected using immunohistochemistry. Expression levels of Prox1, VEGFR3, and VEGFC protein were also detected in fresh CD specimens using western blotting and quantitative polymerase chain reaction [Q-PCR]. Endoscopic recurrence was used as the endpoint. Patients comprised two groups: endoscopic recurrence [Group R+] and no endoscopic recurrence [Group R-].ResultsProx1 protein expression was significantly higher in CD than in normal tissues [p<0.05], as detected using both immunohistochemistry and western blotting. Analysis of inter-relationships revealed significant correlation between Prox1 expression and lymphatic vessel density [p<0.001, r = 0.823]. There was also significant correlation between Prox1 expression and the visceral fat area [VFA] [p= 0.002, r = −0.469]. The Group R- patients had significantly higher Prox1 expression than the Group R+ patients [21.08 ± 1.61 versus 15.64 ± 1.17,p= 0.011]. Also, the lymphatic vessel density value was lower in Group R+ than in Group R- patients [6.02 ± 0.39 versus 8.13 ± 0.59,p= 0.004]. Moreover, there was a significant difference in the VFA between Group R- and Group R+ patients [64.43 ± 7.76 versus 90.44 ± 6.11,p= 0.016]. In addition to Prox1, VEGFC/VEGFR3 was found to increase, which was further confirmed using Q-PCR.ConclusionsProx1 expression could be useful as a protective factor against recurrence in CD patients. The therapeutic role of Prox1 may lead to improved treatments.